(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
BeiGene Ends Ociperlimab Lung Cancer Trial After Futility Analysis
BeiGene has announced the termination of its clinical development program for ociperlimab, following a pre-planned futility analysis of the Phase III AdvanTIG-302 trial. The analysis, conducted by an independent committee, concluded that the drug was unlikely to meet its primary endpoint of improving overall survival (OS) in non-small cell lung cancer (NSCLC) patients. The study evaluated ociperlimab—a humanized IgG1 monoclonal antibody—in combination with Tevimbra (tislelizumab), versus Tevimbra alone or Merck’s Keytruda (pembrolizumab). Ociperlimab was designed to enhance T cell-mediated immune responses against cancer, but results indicated it would not outperform existing therapies. As a result, California-based BeiGene will halt further development. The company, which is rebranding to BeOne Medicines, recently received a positive EMA opinion for Tevimbra as a first-line NSCLC therapy in combination with chemotherapy. BeiGene previously partnered with Novartis on Tevimbra, securing $650 million in 2021, but the agreement was terminated in 2023.
07-04-2025